Microbot Medical obtains Notice of Allowance for a New Patent

News    July 26, 2019
Posted On

Intellectual Property

Microbot Medical has announced that the Israel Intellectual Property Office has issued a Notice of Allowance for its Patent Application number – 231815, which covers a system for reducing shunt stenosis. As Microbot continues to diversify and expand its Intellectual Property (IP) portfolio, it has applied for several patents. With the Notice of Allowance it received recently, the brand is available with 33 issued patents and 18 pending patent applications worldwide.

Harel Gadot, who is the co-founder of Microbot Medical, commented that one of their goals is to explore the market opportunities and leverage their unique robotic technologies. The dialysis market offers remarkable market opportunities for their self-cleaning dialysis shunts and is capable of delivering an alternative to the present standard of care. The latest IP allowance authorizes them to expand and secure their upcoming product offerings while ensuring sustainable competitive advantages. They believe that their company will improve the medical outcomes along with decreasing the healthcare costs as the shunt occlusion is a common yet considerable complication.

The patent revolves around a system to lessen venous stenosis that pertains to the usage of hemodialysis shunts.

The process in this system commences by inserting a cleaning device into the blood vessel. The device is set to be removed (later on) through the first needle bore, while the purified (dialyzed) blood returns into the blood vessel via the second needle bore. When in use, the clearing device contacts the blood vessel’s walls and acts as a passive device that moves down the blood vessel either by the blood flow or a self-sufficient crawling device, like the TipCatTM device of the company. A series of inflatable chambers arranged in sequence forms the basis of TipCatTM.

According to the data provided by the U.S. Renal Data System (USRDS) – per year, around 750,000 patients in the United States and 2 million patients globally get affected by ESRD (end-stage renal disease). As the number of patients is increasing continuously, dialysis is the sole alternative to kidney transplantation in the present times.

Dialysis or hemodialysis refers to a process of purifying the blood of the patient who suffers from kidney failure. The process involves the act of filtering the patient’s blood before it enters back into the body by pumping it with an external circuit.

In general, hemodialysis is scheduled for three sessions per week of 3 to 5 hours each. For more visit: https://www.kashishipr.com/ 

Don’t forget to follow us on social media:

Facebook – https://www.facebook.com/kashishipr/

Twitter – https://twitter.com/kashishipr

Linkedin – https://www.linkedin.com/company/kashishipr/

Pinterest – https://www.pinterest.com/kashishipr/

Tumblr – https://kashishipr.tumblr.com/

leave a Comment